A study led by Shai Shimony, MD, Dana-Farber, revealed the significant impact of molecular ontogeny classification on outcomes among newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents (HMA) +/- venetoclax (VEN).
Dr Shimony's clinical focus is on care of patients with acute leukemia with special interest in acute myeloid leukemia, acute lymphoblastic leukemia and blastic plasmacytoid dentritic cell neoplasm.
